Organic compounds

Addex Therapeutics to Release Half-Year 2021 Financial Results and Host Conference Call on August 5, 2021

Retrieved on: 
Monday, August 2, 2021
Enzyme kinetics, Branches of biology, Organic compounds, Chemistry, Proteins, Dipraglurant, Imidazopyridines, Organofluorides, Allosteric regulation, ASD, Dystonia, Allosteric modulator

Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.

Key Points: 
  • Geneva, Switzerland, August 2, 2021 Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development,today announced that it will issue its Half-Year 2021 financial results on Thursday, August 5, 2021.
  • 1: In the 10 minutes prior to the call start time, call the appropriate participant dial-in number.
  • Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention.
  • Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in Q3 2021.

LianBio Appoints Pascal Qian as General Manager of China

Retrieved on: 
Monday, August 2, 2021
Health, Biotechnology, Chemical compounds, Organic compounds, Aminopyridines, Thioethers, Chloroarenes, Specialty drugs, Protein kinase inhibitors, Palbociclib, Sunitinib, Axitinib, Crizotinib, Qian

LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.

Key Points: 
  • LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced that it has appointed Pascal Qian to the position of China General Manager.
  • Mr. Qian has extensive experience launching products in China, including Verzenio, Tyvyt, Elunate, Afinitor, Votrient, Sutent, Vfend and Singulair.
  • He has also led new product development initiatives in China for multiple globally developed drugs, including crizotinib, axitinib and palbociclib.
  • Mr. Qian most recently served as the Vice President, Head of Oncology Business Unit, at Lilly China.

Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors

Retrieved on: 
Friday, July 30, 2021
Organic compounds, Epidermal growth factor receptor, Oncogenes, KRAS, Chemical compounds, Quinazolines, Cancer, Amines, Chloroarenes, Gefitinib, Icotinib

Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.

Key Points: 
  • Preclinical data demonstrate AFM24s activation of the innate immune system, acting independently of EGFR-expression levels, EGFR-pathway mutations and downstream signal transduction.
  • The published data supported the Investigational New Drug application for the ongoing AFM24 Phase 1/2a dose escalation study.
  • The published data were the basis for the Investigational New Drug (IND) clearance for Affimeds ongoing Phase 1/2a study with AFM24 monotherapy in patients with EGFR expressing solid tumors.
  • AFM24 is effective against many EGFR-positivetumorcells, regardless of EGFR expression level and KRAS/BRAF mutational status within in vitro studies.

Global Vinyl Siding (Cladding) Market Report 2021-2029: Historical Market Trends, Fastest Growing Country Markets and New Product Development - ResearchAndMarkets.com

Retrieved on: 
Friday, July 30, 2021
Construction & Property, Other Construction & Property, Chemistry, Physical sciences, Building materials, Organic compounds, Commodity chemicals, Monomers, Dielectrics, Building engineering, Siding, Polyvinyl chloride, Vinyl siding, Vinyl

The "Global Vinyl Siding (Cladding) Market 2021-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Vinyl Siding (Cladding) Market 2021-2029" report has been added to ResearchAndMarkets.com's offering.
  • This study analyzes global demand for vinyl siding.
  • Vinyl siding encompasses siding made from polyvinyl chloride (PVC).
  • Historical demand (2009, 2014, and 2019) and forecasts for 2024 and 2029 are provided for siding demand by market (in dollars and square meters) and market (in square meters).

UroGen Pharma Announces License and Supply Agreement with Neopharm to Pursue Regulatory Approval and Commercialization for Jelmyto® in Israel

Retrieved on: 
Wednesday, July 28, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Chemical compounds, Organic compounds, Heterocyclic compounds, Aziridines, Breakthrough therapy, Mitomycin C, Oncology, Quinones, Jelmyto®, Upper Tract Urothelial Cancer (UTUC), UroGen Pharma Ltd., Neopharm, JELMYTO®, UPPER TRACT UROTHELIAL CANCER (UTUC), UROGEN PHARMA LTD., NEOPHARM

We are proud to be the first company outside the US to have started the regulatory approval and commercialization process for Jelmyto, demonstrating Israel's importance in geographic expansion.

Key Points: 
  • We are proud to be the first company outside the US to have started the regulatory approval and commercialization process for Jelmyto, demonstrating Israel's importance in geographic expansion.
  • I am confident that our well-established expertise and heritage of collaboration with innovative biopharmaceutical companies will make Jelmyto a success in Israel.
  • UroGen is committed to bringing the promise of Jelmyto to as many patients as possible, as quickly as feasible.
  • JELMYTO and UroGen are registered trademarks of UroGen Pharma, Ltd.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210728005968/en/

Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145

Retrieved on: 
Wednesday, July 28, 2021
Health, Science, Pharmaceutical, Research, Clinical trials, Chemical compounds, Organic compounds, Heterocyclic compounds, Beta-lactamase, Antibiotic, Beta-lactamase inhibitors, β-Lactamase inhibitor, Pharmacokinetics, Cefepime, VNRX-7145, Venatorx Pharmaceuticals, Inc., VNRX-7145, VENATORX PHARMACEUTICALS, INC.

Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.

Key Points: 
  • Venatorx Pharmaceuticals today announced positive top line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial ( ClinicalTrials.gov NCT04243863 ) of VNRX-7145, a novel component of the investigational oral antibiotic combination product.
  • The Phase 1 study was a 2-part, first-in-human dose-ranging study to evaluate the safety and pharmacokinetics (PK) of escalating oral doses of VNRX-7145.
  • Venatorxs two lead antibacterial clinical-stage programs are intravenous (cefepime-taniborbactam) and oral (ceftibuten/VNRX-7145) broad-spectrum beta-lactam/beta-lactamase inhibitor combinations that are in Phase 3 and Phase 1, respectively.
  • In addition, Venatorx is in Phase 1 with its first antiviral compound (VNRX-9945), a Hepatitis B virus inhibitor.

Study: Common Drugs Associated with Increased Risk for Cardiac Arrhythmia and Sudden Death in Elderly Patients

Retrieved on: 
Wednesday, July 28, 2021
Drugs, Chemical compounds, Organic compounds, Tertiary alcohols, Fluoroquinolone antibiotics, Enantiopure drugs, Macrolide antibiotics, Otologicals, Fluconazole, Erythromycin, Ofloxacin, Amoxicillin

This means outcome studies including the measure of sudden death based on large clinical data sets are especially important to assess the risk of drug-induced arrhythmia.

Key Points: 
  • This means outcome studies including the measure of sudden death based on large clinical data sets are especially important to assess the risk of drug-induced arrhythmia.
  • Of the short-term drugs, researchers found the antibiotics levofloxacin increased the risk of cardiac arrhythmia or sudden death by 51% compared to the amoxicillin control, while erythromycin had an increased risk of 63%.
  • The anti-nausea drug ondansetron increased the risk of a cardiac adverse event by 205%, while the antifungal fluconazole increased the risk by 123%.
  • Current patients prescribed the antipsychotics showed an increased risk of arrhythmia or sudden death of 118% compared to patients who never received the drug.

Myovant Sciences Announces Financial Results for First Quarter of Fiscal Year 2021 and Corporate Updates

Retrieved on: 
Wednesday, July 28, 2021
Chemical compounds, Organic compounds, Chemistry, Pfizer, Relugolix/estradiol/norethisterone acetate, Relugolix

First fiscal quarter 2021 net product revenues for ORGOVYX in the U.S. were $10.5 million, driven by increased prescriber demand.

Key Points: 
  • First fiscal quarter 2021 net product revenues for ORGOVYX in the U.S. were $10.5 million, driven by increased prescriber demand.
  • The FDA approval of MYFEMBREE triggered a $100.0 million regulatory milestone payment from Pfizer, which Myovant received in July 2021 (Myovants second fiscal quarter 2021).
  • As previously announced, Myovant will hold a webcast and conference call at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) today, July28, 2021, to discuss financial results for its first fiscal quarter ended June 30, 2021 and corporate updates.
  • Sumitovant is the majority shareholder of Myovant, and wholly owns Urovant Sciences, Enzyvant Therapeutics, Spirovant Sciences, and Altavant Sciences.

FDA Grants Meeting to Petros Pharmaceuticals to Discuss Label Expansion of Erectile Dysfunction Drug STENDRA®

Retrieved on: 
Tuesday, July 27, 2021
Chemical compounds, PDE5 inhibitors, Organic compounds, Chemistry, cGMP-specific phosphodiesterase type 5, Avanafil, Phosphodiesterase, Erectile dysfunction, Sildenafil, Phosphodiesterase inhibitor

"While the PDE5 inhibitor class of erectile dysfunction drugs has a respected history, we believe that the data collected on STENDRA may further differentiate it from other drugs in the class.

Key Points: 
  • "While the PDE5 inhibitor class of erectile dysfunction drugs has a respected history, we believe that the data collected on STENDRA may further differentiate it from other drugs in the class.
  • We look forward to sharing our data with the FDA and discussing the additional necessary steps toward modification of the STENDRA label, and thereby the patient populations that may benefit from treating their erectile dysfunction with STENDRA."
  • Stendra(avanafil), originally launched by Auxilium Pharmaceuticals prior to that company's sale to Endo Pharmaceuticals, is an oral phosphodiesterase 5 (PDE5) inhibitor for the treatment of erectile dysfunction.
  • STENDRA may affect the way other medicines work, and other medicines may affect the way STENDRA works, which may cause side effects.

Koppers Holdings Inc. Schedules Second Quarter 2021 Conference Call

Retrieved on: 
Monday, July 26, 2021
Coal in the United States, Koppers, Organic compounds, Materials, Chemistry, Wood preservation, Polystyrene

Interested parties may access the live audio broadcast toll free by dialing 833-366-1128 in the United States and Canada, or 412-902-6774for international, Conference ID number 10157201.

Key Points: 
  • Interested parties may access the live audio broadcast toll free by dialing 833-366-1128 in the United States and Canada, or 412-902-6774for international, Conference ID number 10157201.
  • Participants are requested to access the call at least five minutes before the scheduled start time to complete a brief registration.
  • Koppers, with corporate headquarters in Pittsburgh, Pennsylvania, is an integrated global provider of treated wood products, wood treatment chemicals and carbon compounds.
  • The stock of Koppers Holdings Inc. is publicly traded on the New York Stock Exchange under the symbol "KOP."